Associations of Ficolins and Mannose-binding Lectin with Acute Myeloid Leukaemia in Adults

Overview

Journal Sci Rep

Specialty Science

Date 2020 Jul 1

PMID 32601370

Citations 16

Authors

Anna Sokolowska

Anna S Swierzko

Gabriela Gajek

Aleksandra Golos

Mateusz Michalski

Mateusz Nowicki

Agnieszka Szala-Pozdziej

Anna Wolska-Washer

Olga Brzezinska

Agnieszka Wierzbowska

Krzysztof Jamroziak

Marek L Kowalski

Steffen Thiel

Misao Matsushita

Jens C Jensenius

Maciej Cedzynski

Affiliations

Soon will be listed here.

Abstract

We investigated clinical associations of ficolins and mannose-binding lectin (MBL) in 157 patients suffering from acute myeloid leukaemia (AML). Concentrations of ficolin-1, ficolin-2, ficolin-3 and MBL (before chemotherapy) in serum were determined as were selected polymorphisms of the corresponding genes (FCN1, FCN2, FCN3 and MBL2). The control group (C) consisted of 267 healthy unrelated individuals. Median level of ficolin-1 in patients was lower (p < 0.000001) while median levels of ficolin-2, ficolin-3 and MBL were higher (p < 0.000001, p < 0.000001 and p = 0.0016, respectively) compared with controls. These findings were generally associated with AML itself, however the highest MBL levels predicted higher risk of severe hospital infections (accompanied with bacteremia and/or fungaemia) (p = 0.012) while the lowest ficolin-1 concentrations tended to be associated with prolonged (> 7 days) fever (p = 0.026). Genotyping indicated an association of G/G homozygosity (corresponding to FCN1 gene - 542 G > A polymorphism) with malignancy [p = 0.004, OR = 2.95, 95% CI (1.41-6.16)]. Based on ROC analysis, ficolin-1, -2 and -3 may be considered candidate supplementary biomarkers of AML. Their high potential to differentiate between patients from non-malignant controls but also from persons suffering from other haematological cancers (multiple myeloma and lymphoma) was demonstrated.

Citing Articles

Impact of Exon 1 polymorphism in the MBL2 gene on MBL serum levels and infection susceptibility in acute lymphoid leukemia.

de Oliveira L, de Souza P, Barbosa A, Mineiro L, Pontes G Sci Rep. 2025; 15(1):244.

PMID: 39747272 PMC: 11696297. DOI: 10.1038/s41598-024-81971-1.

Unveiling ficolins: diagnostic and prognostic biomarkers linked to the Tumor Microenvironment in Lung Cancer.

Zhang Z, Geng X, Yin M, Zhang S, Liu Y, Hu D World J Surg Oncol. 2024; 22(1):273.

PMID: 39390580 PMC: 11468453. DOI: 10.1186/s12957-024-03558-4.

Multi-omics evaluation of the prognostic value and immune signature of FCN1 in pan-cancer and its relationship with proliferation and apoptosis in acute myeloid leukemia.

Zhong F, Song L, Li H, Liu J, Liu C, Guo Q Front Genet. 2024; 15:1425075.

PMID: 39139822 PMC: 11320419. DOI: 10.3389/fgene.2024.1425075.

Complement or insult: the emerging link between complement cascade deficiencies and pathology of myeloid malignancies.

Oakes A, Liu Y, Dubielecka P J Leukoc Biol. 2024; 116(5):966-984.

PMID: 38836653 PMC: 11531810. DOI: 10.1093/jleuko/qiae130.

Loss of ficolin-3 expression is associated with poor prognosis in patients with hepatocellular carcinoma.

Chen C, Yu T, Wu C, Hung W, Lee T, Tang W Int J Med Sci. 2023; 20(8):1091-1096.

PMID: 37484802 PMC: 10357436. DOI: 10.7150/ijms.84729.

References

Austin R, Smyth M, Lane S . Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol Hematol. 2016; 103:62-77. DOI: 10.1016/j.critrevonc.2016.04.020. View

Prada-Arismendy J, Arroyave J, Rothlisberger S . Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2016; 31(1):63-76. DOI: 10.1016/j.blre.2016.08.005. View

Short N, Rytting M, Cortes J . Acute myeloid leukaemia. Lancet. 2018; 392(10147):593-606. PMC: 10230947. DOI: 10.1016/S0140-6736(18)31041-9. View

Shallis R, Wang R, Davidoff A, Ma X, Zeidan A . Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019; 36:70-87. DOI: 10.1016/j.blre.2019.04.005. View

Khayr W, Haddad R, Noor S . Infections in hematological malignancies. Dis Mon. 2012; 58(4):239-49. DOI: 10.1016/j.disamonth.2012.01.001. View

Ruhnke M, Arnold R, Gastmeier P . Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol. 2014; 15(13):e606-e619. DOI: 10.1016/S1470-2045(14)70344-4. View

Gedik H, Simsek F, Kanturk A, Yildirmak T, Arica D, Aydin D . Bloodstream infections in patients with hematological malignancies: which is more fatal - cancer or resistant pathogens?. Ther Clin Risk Manag. 2014; 10:743-52. PMC: 4172031. DOI: 10.2147/TCRM.S68450. View

Nakagawa T, Kawasaki N, Ma Y, Uemura K, Kawasaki T . Antitumor activity of mannan-binding protein. Methods Enzymol. 2003; 363:26-33. DOI: 10.1016/S0076-6879(03)01041-3. View

Yang G, Liang Y, Zheng T, Song R, Wang J, Shi H . FCN2 inhibits epithelial-mesenchymal transition-induced metastasis of hepatocellular carcinoma via TGF-β/Smad signaling. Cancer Lett. 2016; 378(2):80-6. DOI: 10.1016/j.canlet.2016.05.007. View

10.

Ding Q, Shen Y, Li D, Yang J, Yu J, Yin Z . Ficolin-2 triggers antitumor effect by activating macrophages and CD8 T cells. Clin Immunol. 2017; 183:145-157. DOI: 10.1016/j.clim.2017.08.012. View

11.

Michalski M, Swierzko A, Sawicki S, Kaluzynski A, Lukasiewicz J, Maciejewska A . Interactions of ficolin-3 with ovarian cancer cells. Immunobiology. 2019; 224(2):316-324. DOI: 10.1016/j.imbio.2019.01.002. View

12.

Pagowska-Klimek I, Swierzko A, Michalski M, Glowacka E, Szala-Pozdziej A, Sokolowska A . Activation of the lectin pathway of complement by cardiopulmonary bypass contributes to the development of systemic inflammatory response syndrome after paediatric cardiac surgery. Clin Exp Immunol. 2015; 184(2):257-63. PMC: 4837233. DOI: 10.1111/cei.12763. View

13.

Swierzko A, Szala A, Sawicki S, Szemraj J, Sniadecki M, Sokolowska A . Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours. Cancer Immunol Immunother. 2014; 63(11):1129-40. PMC: 4209098. DOI: 10.1007/s00262-014-1579-y. View

14.

Michalski M, Pagowska-Klimek I, Thiel S, Swierzko A, Hansen A, Jensenius J . Factors involved in initiation and regulation of complement lectin pathway influence postoperative outcome after pediatric cardiac surgery involving cardiopulmonary bypass. Sci Rep. 2019; 9(1):2930. PMC: 6393526. DOI: 10.1038/s41598-019-39742-w. View

15.

Hummelshoj T, Munthe-Fog L, Madsen H, Fujita T, Matsushita M, Garred P . Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2. Hum Mol Genet. 2005; 14(12):1651-8. DOI: 10.1093/hmg/ddi173. View

16.

Munthe-Fog L, Hummelshoj T, Hansen B, Koch C, Madsen H, Skjodt K . The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels. Scand J Immunol. 2007; 65(4):383-92. DOI: 10.1111/j.1365-3083.2007.01915.x. View

17.

Cedzynski M, Nuytinck L, Atkinson A, St Swierzko A, Zeman K, Szemraj J . Extremes of L-ficolin concentration in children with recurrent infections are associated with single nucleotide polymorphisms in the FCN2 gene. Clin Exp Immunol. 2007; 150(1):99-104. PMC: 2219292. DOI: 10.1111/j.1365-2249.2007.03471.x. View

18.

Munthe-Fog L, Hummelshoj T, Honore C, Madsen H, Permin H, Garred P . Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. N Engl J Med. 2009; 360(25):2637-44. DOI: 10.1056/NEJMoa0900381. View

19.

Schlapbach L, Thiel S, Aebi C, Hirt A, Leibundgut K, Jensenius J . M-ficolin in children with cancer. Immunobiology. 2010; 216(5):633-8. DOI: 10.1016/j.imbio.2010.09.013. View

20.

Ameye L, Paesmans M, Thiel S, Jensenius J, Aoun M . M-ficolin levels are associated with the occurrence of severe infections in patients with haematological cancer undergoing chemotherapy. Clin Exp Immunol. 2012; 167(2):303-8. PMC: 3278697. DOI: 10.1111/j.1365-2249.2011.04512.x. View